Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200187 | 0.83 | GABRA1 (0.55) | GABRA1LMNACYP1A2CYP3A4GABRG2 | |
| SCHEMBL30202466 | 0.83 | PNMT (0.64) | LMNACYP1A2CYP3A4HTR2CCYP2D6 | |
| SCHEMBL16953380 | 0.83 | CYP1A2 (0.39) | GABRA1LMNACYP1A2CYP3A4GABRG2 | |
| SCHEMBL14121111 | 0.83 | PNMT (0.64) | LMNACYP1A2CYP3A4HTR2CCYP2D6 | |
| SCHEMBL14157339 | 0.83 | PNMT (0.64) | LMNACYP1A2CYP3A4HTR2CCYP2D6 | |
| SCHEMBL24039916 | 0.83 | CYP1A2 (0.39) | GABRA1LMNACYP1A2CYP3A4GABRG2 | |
| SCHEMBL17553331 | 0.83 | CYP3A4 (0.39) | GABRA1LMNACYP1A2CYP3A4GABRG2 | |
| SCHEMBL22154769 | 0.81 | GABRA1 (0.39) | GABRA1LMNACYP1A2CYP3A4GABRG2 | |
| SCHEMBL31521437 | 0.81 | PDE2A (0.41) | GABRA1LMNACYP1A2CYP3A4GABRG2 | |
| Hydrochloric Acid SCHEMBL31521433 | 0.81 | LMNA (0.66) | LMNACYP1A2CYP3A4HTR2CCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230399299-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | AMYGDALA NEUROSCIENCES, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399299-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | AMYGDALA NEUROSCIENCES, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230365557-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2023-10-31 | — | — | US | disclosed |
| WO-2023196454-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20130005689-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8338441-B2 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | BAYER CROPSCIENCE AG (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| US-7956068-B2 | Inhibitors of human immunodeficiency virus replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-07 | — | — | US | disclosed |
| US-20110118249-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20100311735-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | US | disclosed |
| US-20100305115-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100292227-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365557-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | GABRA1 395/4885LMNA 1809/4885CYP1A2 2916/4885 |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | GABRA1 4233/4885LMNA 3007/4885CYP1A2 997/4885 |
| US-20100292227-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, RTF1 | GABRA1 4224/4885LMNA 4178/4885CYP1A2 2138/4885 |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | DHPS, FDPS, DPYD | GABRA1 1953/4885LMNA 4551/4885CYP1A2 862/4885 |
| US-20130005689-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | GABRA1 464/4885LMNA 4840/4885CYP1A2 642/4885 |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | SMN1; SMN2, SNCA, HTT | GABRA1 395/4885LMNA 1809/4885CYP1A2 2916/4885 |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | GABRA1 394/4885LMNA 4847/4885CYP1A2 718/4885 |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | ITGA1, ITGB1, ITGAL | GABRA1 937/4885LMNA 658/4885CYP1A2 3869/4885 |
| US-20110118249-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, CCNY, RTF1 | GABRA1 4218/4885LMNA 3437/4885CYP1A2 2100/4885 |
| US-20100305115-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | CCNY, RTF2, POLR2E | GABRA1 4454/4885LMNA 2685/4885CYP1A2 1818/4885 |
| US-20230399299-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | ALDH1A1, ALDH2, ALDH3A1 | GABRA1 543/4885LMNA 4278/4885CYP1A2 50/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | GABRA1 3975/4885LMNA 2462/4885CYP1A2 3478/4885 |
| US-20100311735-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, POLR1E | GABRA1 4259/4885LMNA 4290/4885CYP1A2 2362/4885 |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | GABRA1 1718/4885LMNA 1162/4885CYP1A2 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.